NASDAQ · ATHE

Alterity Therapeutics Limited news

$3.66+4.57%

Close Sep 29, 2026 · split-adjusted

Articles · 30 days0English, de-duplicated

Positive0

Neutral0

Negative0

About Alterity Therapeutics Limited

No recent articles focused on Alterity Therapeutics Limited.

Also mentions ATHE

Articles that tag ATHE but are mainly about other companies.

Multiple System Atrophy Clinical Trial Pipeline Gains Momentum: 22+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

GlobeNewswire Inc.Aug 26, 1:00 PM ET▲ Positive

Achieved successful End-of-Phase II meeting with FDA in June 2026 for ATH434, gaining alignment on Phase III registrational program design, a critical milestone toward potential NDA submission.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology